Focus recently announced that it entered into a collaboration with Glucotrack to develop an implantable continuous blood glucose monitor (CBGM).
The company said in a LinkedIn post that it expects the long-term, implantable technology to transform how people with diabetes interact with their condition. Focus and Glucotrack want to provide technology that seamlessly integrates into daily life and minimizes device management time.
Under the collaboration, Focus intends to lead the hardware and firmware design for the device. The company says it’s advancing the technology toward first-in-human acute and chronic studies. Glucotrack said last month that it expects to initiate CBGM human trials later this year.
Glucotrack designed its CBGM system to provide continuous, accurate blood glucose monitoring for over two years. Features include a fully subdermal location, eliminating the visibility of an external wearable. Its state-of-the-art sensor technology measures glucose levels directly from the bloodstream and it requires minimal calibration. In preclinical studies, the CBGM demonstrated a mean absolute relative difference (MARD) — a measurement of CGM accuracy — of 4.7% at day 90.
“At Focus, we believe in technology that serves people, not the other way around. This project with Glucotrack underscores our commitment to innovation and our mission to deliver solutions that genuinely improve lives,” Focus wrote in its LinkedIn post.
